Fig. 4

Combination RT and de novo purine synthesis inhibition reduces DMG-H3K27M tumor size and extends mouse survival in vivo. A Schematic of treatment schedule administered to DIPGXIII-bearing Rag1-KO mice. DIPGXIII cells expressing GFP and Luciferase (LUC) (DIPGXIII-GFP/LUC) were orthotopically implanted into the cortex and mice were administered 150mg/kg MMF for 11 days, with 6 intermittent doses of 2Gy RT (red bolts). Schematic was created using BioRender.com. B Spider plot of bioluminescent signal flux values for individual DIPGXIII-GFP/LUC mouse tumors. Blue box indicates the treatment period. C Representative bioluminescent signal images for one mouse per treatment group 24 days after implantation. D Kaplan-Meier survival analysis of Rag1-KO mice bearing treated and untreated DIPGXIII-GFP/LUC orthotopic xenograft tumors (n=10 mice/group). Statistical analysis was performed by comparing individual survival curves of individual treatment groups in GraphPad Prism 10.0